Fig. 5

VCE-004.8 treatment protects from TBI-induced motor impairment. A Experimental design for CCI. B VCE-004.8 administration (20 mg/kg) attenuated the CCI-induced impaired motor performance. Motor recovery was analyzed by Rotarod test prior to and at 24 h, 72 h and 7 days post-CCI. Data are represented as mean ± SEM, and significance was determined by 2-way ANOVA followed by the Tukey’s post hoc test. 24 h, 72 h and 7 days: ***p˂0.0001 CCI + Veh vs Sham; 24 h and 72 h: ###p ˂ 0.0001 CCI + VCE-004.8 vs CCI + Veh; 7 Days: p = 0.0098; ##p˂0.01 CCI + VCE-004.8 vs CCI + Veh. C Weight determination in the different groups of mice. Data are represented as mean ± SEM, and significance was determined by 2-way ANOVA followed by the Tukey’s post hoc test. 24 h: p = 0.0172; *p < 0.05, 72 h: p = 0.0013; **p < 0.01 CCI + Vehicle vs Sham; 24 h ###p < 0.001; 72 h p = 0.0120; #p < 0.05 CCI + VCE-004.8 vs CCI + Vehicle